Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond). 2022;42:937–70.
Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell Lung cancer in CheckMate 227. J Clin Oncol. 2023;41:1200–12.
Article CAS PubMed Google Scholar
Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V. Immunotherapy in non-small cell Lung cancer: past, present, and future directions. Front Oncol. 2022;12: 877594.
Article CAS PubMed PubMed Central Google Scholar
Mielgo-Rubio X, Martín M, Remon J, Higuera O, Calvo V, Jarabo JR, Conde E, Luna J, Provencio M, De Castro J, et al. Targeted therapy moves to earlier stages of non-small-cell Lung cancer: emerging evidence, controversies and future challenges. Future Oncol. 2021;17:4011–25.
Article CAS PubMed Google Scholar
Somasundaram A, Burns TF. The next generation of immunotherapy: keeping lung cancer in check. J Hematol Oncol. 2017;10:87.
Article PubMed PubMed Central Google Scholar
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.
Article CAS PubMed PubMed Central Google Scholar
Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120.
Article PubMed PubMed Central Google Scholar
Zhang X, Zeng L, Li Y, Xu Q, Yang H, Lizaso A, Mao X, Jin R, Zeng Y, Li Q, et al. Anlotinib combined with PD-1 blockade for the treatment of Lung cancer: a real-world retrospective study in China. Cancer Immunol Immunother. 2021;70:2517–28.
Article CAS PubMed Google Scholar
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
Article CAS PubMed PubMed Central Google Scholar
Ye W, Li M, Luo K. Therapies targeting immune cells in tumor microenvironment for non-small cell lung cancer. Pharmaceutics. 2023;15:1788.
Article CAS PubMed PubMed Central Google Scholar
Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34:1675–99.
Article CAS PubMed Google Scholar
Raeisi M, Zehtabi M, Velaei K, Fayyazpour P, Aghaei N, Mehdizadeh A. Anoikis in cancer: the role of lipid signaling. Cell Biol Int. 2022;46:1717–28.
Article CAS PubMed Google Scholar
Wang G, Qiu M, Xing X, Zhou J, Yao H, Li M, Yin R, Hou Y, Li Y, Pan S, et al. Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis. Sci Transl Med. 2022;14: eabk2756.
Article CAS PubMed Google Scholar
Rossi Sebastiano M, Konstantinidou G. Targeting long chain Acyl-CoA synthetases for cancer therapy. Int J Mol Sci. 2019;20(15):3624.
Article PubMed PubMed Central Google Scholar
Eltayeb K, La Monica S, Tiseo M, Alfieri R, Fumarola C. Reprogramming of lipid metabolism in lung cancer: an overview with focus on EGFR-Mutated non-small cell lung cancer. Cells. 2022;11: 413.
Article CAS PubMed PubMed Central Google Scholar
Song DD, Zhou JH, Sheng R. Regulation and function of sphingosine kinase 2 in diseases. Histol Histopathol. 2018;33:433–45.
Conforti F, Zucali PA, Pala L, Catania C, Bagnardi V, Sala I, Della Vigna P, Perrino M, Zagami P, Corti C, et al. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:1287–96.
Article CAS PubMed Google Scholar
Xuan Q, Zheng F, Yu D, Ouyang Y, Zhao X, Hu C, Xu G. Rapid lipidomic profiling based on ultra-high performance liquid chromatography-mass spectrometry and its application in diabetic retinopathy. Anal Bioanal Chem. 2020;412:3585–94.
Article CAS PubMed Google Scholar
Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc. 2011;6:743–60.
Article CAS PubMed Google Scholar
Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N, Xia J. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17:1735–61.
Article CAS PubMed Google Scholar
Wang Y, Shi X, Qi Q, Ye B, Zou Z. Safety of anlotinib capsules combined with PD-1 inhibitor camrelizumab in the third-line treatment of advanced non-small-cell lung cancer and their effect on serum tumor markers. J Healthc Eng. 2021;2021:2338800.
Article PubMed PubMed Central Google Scholar
Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell Lung cancer. Cancer Med. 2023;12:5372–83.
Article CAS PubMed Google Scholar
Merino Salvador M, Gómez de Cedrón M, Moreno Rubio J, Falagán Martínez S, Sánchez Martínez R, Casado E, de Ramírez A, Sereno M. Lipid metabolism and lung cancer. Crit Rev Oncol Hematol. 2017;112:31–40.
Ji Z, Shen Y, Feng X, Kong Y, Shao Y, Meng J, Zhang X, Yang G. Deregulation of lipid metabolism: the critical factors in ovarian cancer. Front Oncol. 2020;10: 593017.
Article PubMed PubMed Central Google Scholar
Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218:e20201606.
Article CAS PubMed Google Scholar
Chen RY, Li ZY, Yuan YL, Zhu ZJ, Zhang J, Xin T, Zhang XJ. A comprehensive analysis of metabolomics and transcriptomics in non-small cell Lung cancer. PLoS ONE. 2020;15: e0232272.
Xiang Y, Zhao Q, Wu Y, Liu X, Zhu J, Yu Y, Su X, Xu K, Jiang Y, Zhao G. Serum Metabolomics Profiling reveals metabolic alterations prior to a diagnosis with Non-small Cell Lung Cancer among Chinese Community residents: a prospective nested case-control study. Metabolites. 2022;12: 906.
Article CAS PubMed PubMed Central Google Scholar
Pan Z, Wang K, Wang X, Jia Z, Yang Y, Duan Y, Huang L, Wu ZX, Zhang JY, Ding X. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. Mol Cancer. 2022;21:77.
Article CAS PubMed PubMed Central Google Scholar
Wenk MR, Choi H. Abundant circulating lipids - a new opportunity for NSCLC detection? Nat Rev Clin Oncol. 2022;19:361–2.
Albanes D, Alcala K, Alcala N, Amos CI, Arslan AA, Bassett JK, Brennan P, Cai Q, Chen C, Feng X, et al. The blood proteome of imminent lung cancer diagnosis. Nat Commun. 2023;14:3042.
Xia T, Ren H, Zhang W, Xia Y. Lipidome-wide characterization of phosphatidylinositols and phosphatidylglycerols on CC location level. Anal Chim Acta. 2020;1128:107–15.
Article CAS PubMed PubMed Central Google Scholar
Liu Q, Luo Q, Halim A, Song G. Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39–45.
Article CAS PubMed Google Scholar
Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, Loda M, Kinlaw WB, Swinnen JV. Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245–93.
Article CAS PubMed PubMed Central Google Scholar
Kiebish MA, Han X, Cheng H, Chuang JH, Seyfried TN. Cardiolipin and electron transport chain abnormalities in mouse Brain Tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res. 2008;49:2545–56.
Article CAS PubMed PubMed Central Google Scholar
Chen W-W, Chao Y-J, Chang W-H, Chan J-F, Hsu Y-HH. Phosphatidylglycerol incorporates into Cardiolipin to improve mitochondrial activity and inhibits inflammation. Sci Rep. 2018;8:4919.
Comments (0)